Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

FEBS Letters

Volumn 584, Issue 12, 2010, Pages 2670-2680

  Lofblom J ^a   Feldwisch, J ^b,c   Tolmachev, V ^b   Carlsson, J ^b   Stahl S ^a   Frejd, F Y ^b,c  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Affibody AB   (Sweden)

Author keywords

Affibody molecule; Alternative scaffold; Biotherapy; Combinatorial protein engineering; Molecular imaging; Phage display

Indexed keywords

ALEMTUZUMAB; AMINO ACID DERIVATIVE; AMYLOID BETA PROTEIN; COPOLYMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM 68; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOLIPOSOME; IMMUNOTOXIN; LIPOSOME; LUTETIUM 177; MACROGOL; MONOCLONAL ANTIBODY; NANOPARTICLE; PERTUZUMAB; POLYMER; PROTEIN ANTIBODY; PROTEIN DERIVATIVE; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RADIOISOTOPE; RHENIUM 186; SCAFFOLD PROTEIN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; YTTRIUM 90;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BIOENGINEERING; BIOTECHNOLOGY; BREAST BIOPSY; BREAST CANCER; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; GENETIC ENGINEERING; HUMAN; IMAGING SYSTEM; LIGAND BINDING; MOLECULAR LIBRARY; NOMENCLATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR; VIRUS PARTICLE;

AFFINITY LABELS; AMINO ACID SEQUENCE; ANIMALS; BIOTECHNOLOGY; HUMANS; MOLECULAR IMAGING; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TERMINOLOGY AS TOPIC;

EID: 77953130101     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.04.014     Document Type: Review

References (91)

1. Nygren P.Å., Skerra A. Binding proteins from alternative scaffolds. J. Immunol. Methods 2004, 290:3-28.
2. Binz H.K., Amstutz P., Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 2005, 23:1257-1268.
3. Uhlén M., Guss B., Nilsson B., Gatenbeck S., Philipson L., Lindberg M. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J. Biol. Chem. 1984, 259:1695-1702.
4. Myers J.K., Oas T.G. Preorganized secondary structure as an important determinant of fast protein folding. Nat. Struct. Biol. 2001, 8:552-558.
5. Nilsson B., et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987, 1:107-113.
6. Nord K., Nilsson J., Nilsson B., Uhlén M., Nygren P.Å. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 1995, 8:601-608.
7. Nord K., Gunneriusson E., Ringdahl J., Ståhl S., Uhlén M., Nygren P.Å. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol. 1997, 15:772-777.
8. Nygren P.Å. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008, 275:2668-2676.
9. Gunneriusson E., Nord K., Uhlén M., Nygren P.Å. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng. 1999, 12:873-878.
10. Orlova A., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006, 66:4339-4348.
11. Hoyer W., Grönwall C., Jonsson A., Ståhl S., Härd T. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. USA 2008, 105:5099-5104.
12. Engfeldt T., Renberg B., Brumer H., Nygren P.Å., Karlström A.E. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005, 6:1043-1050.
13. Friedman M., et al. Engineering and characterization of a bispecific HER2×EGFR-binding affibody molecule. Biotechnol. Appl. Biochem. 2009, 54:121-131.
14. Bowley D.R., Labrijn A.F., Zwick M.B., Burton D.R. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng. Des. Sel. 2007, 20:81-90.
15. Nord O., Uhlén M., Nygren P.Å. Microbead display of proteins by cell-free expression of anchored DNA. J. Biotechnol. 2003, 106:1-13.
16. Koch H., Grafe N., Schiess R., Plückthun A. Direct selection of antibodies from complex libraries with the protein fragment complementation assay. J. Mol. Biol. 2006, 357:427-441.
17. Secco P., et al. Antibody library selection by the {beta}-lactamase protein fragment complementation assay. Protein Eng. Des. Sel. 2009, 22:149-158.
18. Amstutz P., Koch H., Binz H.K., Deuber S.A., Plückthun A. Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Eng. Des. Sel. 2006, 19:219-229.
19. Löfdahl P.Å., Nord O., Janzon L., Nygren P.Å. Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. Nat. Biotechnol. 2009, 26:251-259.
20. Löfdahl P.Å., Nygren P.Å. Affinity maturation of a TNFalpha-binding affibody molecule by Darwinian survival selection. Biotechnol. Appl. Biochem. 2010, 55:111-120.
21. Kronqvist N., Löfblom J., Jonsson A., Wernérus H., Ståhl S. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng. Des. Sel. 2008, 21:247-255.
22. Jonsson A., Wållberg H., Herne N., Ståhl S., Frejd F.Y. Generation of tumour-necrosis-factor-alpha-specific affibody1 molecules capable of blocking receptor binding in vitro. Biotechnol. Appl. Biochem. 2009, 54:93-103.
23. Baum R., Prasad V. Molecular imaging for monitoring therapy response. Clinical Nuclear Medicine 2007, 57-79. Oxford University Press, London. G. Cook, M. Maisey, K. Britton, V. Chengazi (Eds.).
24. Boss D.S., Olmos R.V., Sinaasappel M., Beijnen J.H., Schellens J.H. Application of PET/CT in the development of novel anticancer drugs. Oncologist 2008, 13:25-38.
25. Brindle K. New approaches for imaging tumour responses to treatment. Nat. Rev. Cancer 2008, 8:94-107.
26. Tolmachev V., Orlova A., Nilsson F.Y., Feldwisch J., Wennborg A., Abrahmsén L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin. Biol. Ther. 2007, 7:555-568.
27. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr. Pharm. Des. 2008, 14:2999-3019.
28. Zahnd C., et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 2010, 70:1595-1605.
29. Miao, Z., Levi, J. and Cheng, Z. (in press) Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids. doi:10.1007/s00726-010-0503-9.
30. Tolmachev V., Rosik D., Wållberg H., Sjoberg A., Sandström M., Hansson M., Wennborg A., Orlova A. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:613-622.
31. Wikman M., Steffen A.C., Gunneriusson E., Tolmachev V., Adams G.P., Carlsson J., Ståhl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel. 2004, 17:455-462.
32. Ahlgren S., et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug. Chem. 2008, 19:235-243.
33. Feldwisch J., et al. Design of an optimized scaffold for affibody molecules. J. Mol. Biol. 2010, 398(2):232-247.
34. Orlova A., Feldwisch J., Abrahmsén L., Tolmachev V. Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother. Radiopharm. 2007, 22:573-584.
35. Tolmachev V., Orlova A. Update on Affibody molecules for in vivo imaging of targets for cancer therapy. Miner. Biotechnol. 2009, 21:21-30.
36. Orlova A., et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007, 67:2178-2186.
37. Tolmachev, V., Velikyan, I., Sandstrom, M. and Orlova, A. (in press) A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur. J. Nucl. Med. Mol. Imaging. doi:10.1007/s00259-009-1367-7.
38. Baum, R., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V. and Feldwisch, J. (in press) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J. Nucl. Med. doi:10.2967/jnumed.109.073239.
39. Webster J.M., Zhang R., Gambhir S.S., Cheng Z., Syud F.A. Engineered two-helix small proteins for molecular recognition. Chembiochem 2009, 10:1293-1296.
40. Ren G., Zhang R., Liu Z., Webster J.M., Miao Z., Gambhir S.S., Syud F.A., Cheng Z. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J. Nucl. Med. 2009, 50:1492-1499.
41. Ahlgren, S., et al. (in press) Targeting of HER2-expressing tumors using 111In-ABY-025, a second generation Affibody molecule with a fundamentally re-engineered scaffold. J. Nucl. Med.
42. Wållberg H., Ahlgren S., Widström C., Orlova A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys affibody molecule for targeting of HER2-expressing tumors. Mol. Imaging Biol. 2010, 12:54-62.
43. Kiesewetter D.O., Kramer-Marek G., Ma Y., Capala J. Radiolabeling of HER2 specific Affibody® molecule with F-18. J. Fluor. Chem. 2008, 129:799-805.
44. Kramer-Marek G., Kiesewetter D.O., Martiniova L., Jagoda E., Lee S.B., Capala J. [18F]FBEM-ZHER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1008-1018.
45. Cheng Z., et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J. Nucl. Med. 2008, 49:804-813.
46. Kinoshita M., Yoshioka Y., Okita Y., Hashimoto N., Yoshimine T. MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody. Contrast Media Mol. Imaging 2010, 5:18-22.
47. Lee S.B., Hassan M., Fisher R., Chertov O., Chernomordik V., Kramer-Marek G., Gandjbakhche A., Capala J. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin. Cancer Res. 2008, 14:3840-3849.
48. Gong H., Kovar J., Little G., Chen H., Olive D.M. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia 2010, 12:139-149.
49. Pastan I., Hassan R., Fitzgerald D.J., Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 2006, 6:559-565.
50. Zielinski R., et al. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J. Immunother. 2009, 32:817-825.
51. Tolmachev V., Nilsson F.Y., Widström C., Andersson K., Rosik D., Gedda L., Wennborg A., Orlova A. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J. Nucl. Med. 2006, 47:846-853.
52. Fortin M.A., Orlova A., Malmström P.U., Tolmachev V. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int. J. Mol. Med. 2007, 19:285-291.
53. Wållberg H., Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother. Radiopharm. 2008, 23:435-442.
54. Tolmachev V., Mume E., Sjöberg S., Frejd F.Y., Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:692-701.
55. Orlova A., Tran T.A., Ekblad T., Karlström A.E., Tolmachev V. 186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:260-269.
56. Tolmachev V., et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007, 67:2773-2782.
57. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 2002, 43:693-713.
58. Persson M., Gedda L., Lundqvist H., Tolmachev V., Nordgren H., Malmström P.U., Carlsson J. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res. 2007, 67:326-331.
59. Adams G.P., et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004, 64:6200-6206.
60. Alexis F., et al. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem 2008, 3:1839-1843.
61. Canine B.F., Wang Y., Hatefi A. Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. J. Control Release 2009, 138:188-196.
62. Beuttler J., Rothdiener M., Müller D., Frejd F.Y., Kontermann R.E. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug. Chem. 2009, 20:1201-1208.
63. Puri A., et al. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J. Liposome Res. 2008, 18:293-307.
64. Myhre S., Henning P., Friedman M., Ståhl S., Lindholm L., Magnusson M.K. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther. 2009, 16:252-261.
65. Magnusson M.K., et al. Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Ther. 2007, 14:468-479.
66. Myhre S., et al. Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Gene Ther. 2007, 14:376-381.
67. Belousova N., Mikheeva G., Gelovani J., Krasnykh V. Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J. Virol. 2008, 82:630-637.
68. Sandström K., Xu Z., Forsberg G., Nygren P.Å. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng. 2003, 16:691-697.
69. Grönwall C., Snelders E., Palm A.J., Eriksson F., Herne N., Ståhl S. Generation of Affibody ligands binding interleukin-2 receptor alpha/CD25. Biotechnol. Appl. Biochem. 2008, 50:97-112.
70. Li, J., Lundberg, E., Vernet, E., Larsson, B., Höidén-Guthenberg, I. and Gräslund, T. (in press) Selection of affibody molecules to the ligand binding site of the insulin-like growth factor-1 receptor. Biotechnol. Appl. Biochem. doi:10.1042/BA20090226.
71. Nordberg E., et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl. Med. Biol. 2007, 34:609-618.
72. Grönwall C., Jonsson A., Lindström S., Gunneriusson E., Ståhl S., Herne N. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 2007, 128:162-183.
73. Luheshi, L.M., et al. (in press) Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo. PLoS Biol. doi:10.1371/journal.pbio.1000334.
74. Vernet E., Konrad A., Lundberg E., Nygren P.Å., Gräslund T. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. J. Immunol. Methods 2008, 338:1-6.
75. Vernet E., Lundberg E., Friedman M., Rigamonti N., Klausing S., Nygren P.Å., Gräslund T. Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain. Nat. Biotechnol. 2009, 25:417-423.
76. Lundberg E., Brismar H., Gräslund T. Selection and characterization of Affibody ligands to the transcription factor c-Jun. Biotechnol. Appl. Biochem. 2009, 52:17-27.
77. Nord K., Gunneriusson E., Uhlén M., Nygren P.Å. Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. J. Biotechnol. 2000, 80:45-54.
78. Andersson C., Hansson M., Power U., Nygren P.-Å., Ståhl S. Mammalian cell production of a respiratory syncytial virus (RSV) candidate vaccine recovered using a product-specific affinity column. Biotechnol. Appl. Biochem. 2001, 34:25-32.
79. Nord K., Nord O., Uhlén M., Kelley B., Ljungqvist C., Nygren P.Å. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur. J. Biochem. 2001, 268:4269-4277.
80. Grönwall C., Sjöberg A., Ramström M., Höidén-Guthenberg I., Hober S., Jonasson P., Ståhl S. Affibody-mediated transferrin depletion for proteomics applications. Biotechnol. J. 2007, 2:1389-1398.
81. Rönnmark J., Grönlund H., Uhlén M., Nygren P.Å. Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. Eur. J. Biochem. 2002, 269:2647-2655.
82. Hedhammar M., Gräslund T., Uhlén M., Hober S. Negatively charged purification tags for selective anion-exchange recovery. Protein Eng. Des. Sel. 2004, 17:779-786.
83. Hedhammar M., Hober S. Z(basic)-a novel purification tag for efficient protein recovery. J. Chromatogr. A 2007, 1161:22-28.
84. Rönnmark J., Hansson M., Nguyen T., Uhlén M., Robert A., Ståhl S., Nygren P.Å. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J. Immunol. Methods 2002, 261:199-211.
85. Rönnmark J., Kampf C., Asplund A., Höidén-Guthenberg I., Wester K., Pontén F., Uhlén M., Nygren P.Å. Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. J. Immunol. Methods 2003, 281:149-160.
86. Lundberg E., Höidén-Guthenberg I., Larsson B., Uhlén M., Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J. Immunol. Methods 2007, 319:53-63.
87. Gunneriusson E., Samuelson P., Ringdahl J., Grönlund H., Nygren P.Å., Ståhl S. Staphylococcal surface display of immunoglobulin A (IgA)- and IgE-specific in vitro-selected binding proteins (affibodies) based on Staphylococcus aureus protein A. Appl. Environ. Microbiol. 1999, 65:4134-4140.
88. Renberg B., Nordin J., Merca A., Uhlén M., Feldwisch J., Nygren P.Å., Karlström A.E. Affibody molecules in protein capture microarrays: evaluation of multidomain ligands and different detection formats. J. Proteome Res. 2007, 6:171-179.
89. Andersson M., Rönnmark J., Areström I., Nygren P.Å., Ahlborg N. Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. J. Immunol. Methods 2003, 283:225-234.
90. Lyakhov I., Zielinski R., Kuban M., Kramer-Marek G., Fisher R., Chertov O., Bindu L., Capala J. HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem 2010, 11:345-350.
91. Renberg B., Nygren P.Å., Eklund M., Karlström A.E. Fluorescence resonance energy transfer-based detection of analytes using antiidiotypic affinity protein pairs. Anal. Biochem. 2004, 334:72-80.